June 28, 2019

Jonathan Rourke, Co-Founder & CEO, MitraSpan

Show Notes
Transcript

Jonathan (Jon) is co-founder & CEO at MitraSpan —a medical device development company that is exploring minimally invasive mitral valve repair techniques for treating type IIIb functional mitral regurgitation in heart failure patients.

Jon's career in medical devices and cardiology began in 1991 in the ultrasound imaging business at Hewlett-Packard Medical Products (now owned by Philips). He worked on engineering challenges related to manufacturing high-frequency ultrasound transducers for both TTE and TEE devices. In 1995, he led the IVUS catheter program, a joint venture first with Boston Scientific and later Guidant. This business was later spun out to Volcano and then recently acquired back by Philips. In 1999, Jon moved to the venture-backed startup world where he has remained for now 20 years first as VP of R&D at Endotex where he focused on the development of a carotid stent. He led this program through successful feasibility studies and pivotal study launch. Following that and FDA-PMA approval, Endotex was acquired by BSX. In 2001, Jon joined TransMedics as VP of R&D and lead development efforts through the successful completion of the first full venture round. Transmedics recently filed for an IPO and is a pioneering company focused on the normothermic, sanguineous, functional preservation of organs for transplantation.

Since 2002, Jon has led a succession of development and clinical trial efforts in the structural heart and mitral repair fields. First, at Viacor he served as both VP of R&D and CEO; and later at Harpoon, he helped arrange for the spinout of IP and the securement of initial program funding. Now, at MitraSpan he continues to innovate on potential breakthrough structural techniques.

WEBVTT

00:00:04.190 --> 00:00:07.870
Welcome to the LATAM Medtech Leaders Podcast.

00:00:08.169 --> 00:00:12.669
This is a weekly conversation with medtech leaders who have succeeded in Latin America.

00:00:12.281 --> 00:00:17.179
Today our guest is Jon Rourke.

00:00:18.019 --> 00:00:20.089
Hey Jon, It's great to have you on the show today.

00:00:21.481 --> 00:00:21.989
Thanks, Julio.

00:00:22.019 --> 00:00:22.710
Good to have you.

00:00:23.059 --> 00:00:23.629
Excellent.

00:00:23.690 --> 00:00:39.829
Well listeners, John is the co-founder& CEO at MitraSpan—a medical device development company that is exploring minimally invasive mitral valve repair techniques for treating type IIIb functional mitral regurgitation in heart failure patients.

00:00:44.020 --> 00:00:53.780
Since 2002, Jon has led a succession of development and clinical trial efforts in the structural heart and mitral repair fields.

00:00:53.960 --> 00:01:05.269
First, at Viacor he served as both VP of R&D and CEO; and later at Harpoon, he helped arrange for the spinout of IP and the securement of initial program funding.

00:01:05.271 --> 00:01:09.230
Now, at MitraSpan he continues to innovate on potential breakthrough structural techniques.

00:01:09.230 --> 00:01:15.680
Jon's academic credentials include B.S.

00:01:15.680 --> 00:01:16.340
and M.S.

00:01:16.340 --> 00:01:21.319
degrees in Mechanical and Electrical Engineering from Worcester Tech and MIT respectively.

00:01:22.459 --> 00:01:26.480
So, John is a truly a privilege to have you here on the show today.

00:01:27.170 --> 00:01:31.790
You and I work in Colombia a few years ago, like what, five, seven years ago?

00:01:31.959 --> 00:01:38.590
No, not that many, but yeah, just about five years ago, I first met Pedro in Miami and I thought he was a baseball player.

00:01:38.111 --> 00:01:47.310
Pedro Martínez is my favorite Red Sox player so when I heard he had moved into cardiology, I...

00:01:48.129 --> 00:01:51.370
Well, for the listeners, Pedro Martínez-Clark is my brother.

00:01:51.370 --> 00:01:57.280
He's a Harvard trained interventional cardiologist and he has a medical practice in Miami.

00:01:57.640 --> 00:02:02.230
And by the time he met Jon, he was a professor at the University of Miami.

00:02:02.230 --> 00:02:07.000
And uh, that's how we all got involved with clinical research in Latin America.

00:02:07.569 --> 00:02:17.889
So Jon, let's start the show by asking you a general question about your story and your journey to Latin America.

00:02:17.890 --> 00:02:19.900
How do you get involved with the region?

00:02:20.360 --> 00:02:41.030
Well, I started out as an engineer focused on making things and once through a few stops and I ended up working on Uli Packard medical products, which are for those who remember that was a very big and still is a very big player in medical devices for major activity being cardiac ultrasound.

00:02:41.659 --> 00:02:52.819
And as things happened, I became involved with first with tee probes, which were a huge success in the nineties really changed cardiac surgery.

00:02:53.210 --> 00:02:58.819
But then I ended up heading up the IVUS Catheter program that you'll attack or IVUS imaging.

00:03:00.139 --> 00:03:14.000
And at the end of the nineties I think people who know that HP sold their medical business to a succession of companies, they IVUS ended up getting sold to volcano and the whole medical business ended up getting sold to Philips.

00:03:14.509 --> 00:03:40.039
And at that point in time, I joined a startup that I had met through the IVUS business called Endotechs, which was a carotid stent development program, which included a lot of former IVUS people for strange reasons And in that era, Argentina was one of the real leaders in both cardiac stenting and carotid stenting.

00:03:40.159 --> 00:03:44.419
They had a number of the important players, one proti and Hugo lung Darrow.

00:03:44.599 --> 00:03:53.300
And so I first did clinical work round in 1999 and 2000 in Argentina and then in Chili and carotid stenting.

00:03:53.930 --> 00:03:58.909
And I found it a magnificent experience, very different from anything I had done up until then.

00:03:58.911 --> 00:04:26.509
And I really both enjoyed it and saw the, you know, it's a very different approach to medicine than you get, you know, up until that point, my exposure had been strictly major u s research centers where things are done a certain way and it was quite different to be in a South American clinic with run by a world ranked clinician, which was our experience in both Argentina and Chile.

00:04:27.019 --> 00:04:46.329
And then from there I went through, as you mentioned earlier, I worked for a time on transplantation for a company called Trans medics And then from there got involved in the, what has been the structural now booming structural Hartfield first on a coronary sinus program called viacore.

00:04:46.790 --> 00:04:54.350
And then for a time I work with Dr Gammy in Baltimore on Harpoon, which was a coral replacement effort.

00:04:54.410 --> 00:05:07.069
And then from there we've been working on a spanning method of repairing the Mitral Valve, something originally conceived by among others, Craig Miller at Stanford.

00:05:07.579 --> 00:05:22.519
I mean that is to tempt to repair the mitral valve by suturing directly across the orifice of the valve, which gives you a tremendous control of anterior posterior dilation.

00:05:23.000 --> 00:05:27.949
But of course raises complicated anchoring and suturing issues.

00:05:28.160 --> 00:05:31.879
And so to this day I continue to, uh, plug in the field.

00:05:32.000 --> 00:05:32.480
Excellent.

00:05:32.480 --> 00:05:32.870
Jon.

00:05:33.259 --> 00:05:37.759
Hey, by the way, I met Bill Neeland in Colombia at Harpoon.

00:05:37.879 --> 00:05:43.550
He traveled to meet a candidate investigator that we found for him a couple of years ago.

00:05:43.939 --> 00:05:44.240
Yeah.

00:05:44.449 --> 00:05:46.550
Cause he's onto a new endeavor now, isn't it?

00:05:46.759 --> 00:05:47.569
Yeah, I know.

00:05:47.600 --> 00:05:54.889
He called me a few days ago because he has a new technology that he wants to also test in Colombia.

00:05:55.060 --> 00:05:59.430
Bill came in at Harpoon after, at the time I was working on Harpoon.

00:05:59.430 --> 00:06:07.439
Harpoon consisted of the very brilliant and passionate Jim Gammy and some very clever idea.

00:06:07.980 --> 00:06:34.589
And during the period of time I worked with them, we were concerned with how to secure the intellectual property from the university into an independent corporation so that he could raise funding and I worked with them to the point where we had independent external funding and licenses to the patents and a free path ahead.

00:06:34.709 --> 00:06:44.160
But I had other proposals in the space that I chose to pursue those, but I remain a huge fan of both the clinicians and the a work they're doing.

00:06:44.220 --> 00:06:45.750
They're very focused.

00:06:46.319 --> 00:07:08.040
Dr Gammy himself, I think you could argue he's the finest coral replacement clinician in the u s one thing I always noticed is who's held in high esteem in private by other surgeons and I can safely report that he's held in the highest esteem by his peers when they're speaking off the record.

00:07:08.129 --> 00:07:15.959
That's something I'm always looking for, not necessarily who has the biggest name on the podium or whatever.

00:07:15.961 --> 00:07:19.259
There's some people that have achieved gloss without substance.

00:07:19.550 --> 00:07:21.379
Yeah, that's what I heard as well.

00:07:21.720 --> 00:07:26.509
All right John, so let's move on to my next question.

00:07:27.259 --> 00:07:32.959
What's your overall perception of Latin America as a place to conduct first in human clinical research?

00:07:33.790 --> 00:07:46.779
My experiences focused on three countries and three different devices and I found it enormously a favorable in my mind what for very specific reasons.

00:07:46.781 --> 00:08:04.600
In other words, I don't think it's all things to all people, but I'm very in favor of it, particularly in the we're particular sweet spot of early feasibility where I think South America is at its very best and it's the situations where you can find alignment.

00:08:04.870 --> 00:08:08.860
It's a breed of clinician that I think South America uniquely created.

00:08:08.889 --> 00:08:54.250
And this is where everybody certainly knows about Favaloro and I think it's a kind of clinician they have, not that all clinicians don't have a sense of service, but I see in South America, you walk in the clinic with a pair of us eyes and you realize these clinicians have an unlimited number of patients that are dependent on them in a way that they can't just throw a hissy fit and goes, you know the way you can, when you live in Boston, you don't like doctor a, you go to doctor B, your doctor see your doctor e and when you see a South American clinics serving a much more complex population, it's a more in need population is a big part of what's in the lobby of that hospital.

00:08:54.460 --> 00:09:02.970
And think the clinicians have this passion and commitment to service that you just feel in your bones when you're around them.

00:09:03.929 --> 00:09:13.500
And so the ones that work in that environment and at the same time choose to take a leadership role in pushing new therapies.

00:09:13.500 --> 00:09:17.940
They're very special people and it's greatly rewarding to work with them.

00:09:17.970 --> 00:09:24.480
And I think they have a skillset that develops on a different parameters than in some of the more westernized settings.

00:09:24.830 --> 00:09:28.860
And that's kind of the first thing I think of when I think of a South American clinic.

00:09:29.470 --> 00:09:32.500
In what specific countries have you being involved in?

00:09:33.330 --> 00:09:35.940
Argentina, Chile and Colombia.

00:09:36.379 --> 00:09:36.950
Excellent.

00:09:37.490 --> 00:09:48.620
All right, so let's get a little deeper into some of the experiences you've had and if you could also provide tips or best practices to listeners, it'd be fantastic, Jon.

00:09:49.129 --> 00:09:53.360
So let's talk about the selection of a principle investigator.

00:09:54.110 --> 00:09:58.789
I mean, how do you go about it, and was usually the process that you have for that?

00:09:59.950 --> 00:10:06.279
Yeah, and I would say it's selection of a principle investigator, word of mouth, reputation.

00:10:06.759 --> 00:10:15.009
And then than than I have to say to a lesser extent publications, but word of mouth and personal recommendations.

00:10:15.240 --> 00:10:27.100
You know, certainly that's how in the period of time when I got started in Argentina, the clinicians there were just at the forefront of the thing that particularly stenting and embolic protection, they were real leaders.

00:10:27.190 --> 00:10:30.129
So I think that, I think this is where I'm speaking back to you.

00:10:30.130 --> 00:10:44.769
You would know, I think my advice for anybody, you want to talk to people who have actual experience in the country, in the center with the clinicians you're considering so that you can feel out whether this is a good match for what you're trying to do.

00:10:45.220 --> 00:10:48.070
Because as we know, there's such a wide range of situations.

00:10:48.340 --> 00:10:54.789
Am I trying on a new vascular closure device, my trying on a new guidewire, my trying out a new stent.

00:10:54.791 --> 00:10:56.860
Am I trying out a new val?

00:10:56.980 --> 00:11:00.940
Each level of the game creates, I've never had the experience.

00:11:00.941 --> 00:11:08.350
For instance, I'm sure it goes on, but going to South America to enroll people in like a say a closure device study.

00:11:08.789 --> 00:11:11.200
Well I can't really give you a lot insight there.

00:11:11.289 --> 00:11:22.600
Things where operative excellence are really not a big factor where you're really just looking for enrollment, data integrity and regulatory process, quality process, that kind of thing.

00:11:23.259 --> 00:11:31.149
I've always been involved in settings where operative excellence was of paramount importance.

00:11:31.450 --> 00:11:34.570
So anything I'm saying is speaking only to that realm.

00:11:34.571 --> 00:11:42.850
When I'm saying early feasibility, I'm talking about early feasibility on things where you're depending upon the operative team to be world-class.

00:11:43.610 --> 00:11:43.940
Okay.

00:11:43.941 --> 00:11:48.110
I'm curious why you laugh about publications a little earlier.

00:11:48.529 --> 00:11:50.690
Why you think,

00:11:51.039 --> 00:11:57.649
well, I think I've worked with people in South American clinics that I just hold in the highest regard.

00:11:57.650 --> 00:12:07.009
We certainly among us engineers in the field, there's always the cut to the chase question of would I recommend this clinician for a family member?

00:12:07.070 --> 00:12:13.009
But what engineers ask each other is, yeah, yeah, if my mother needed the procedure, are we going to this guy?

00:12:13.460 --> 00:12:15.769
And that's our immutable question.

00:12:15.770 --> 00:12:19.809
And when you're asking that question, I don't care if he's got 1100 publications, I care.

00:12:19.899 --> 00:12:21.440
I was the person needs, you're going to come out.

00:12:21.590 --> 00:12:32.750
And I worked with clinicians in South America that I just haven't seen a big footprint, um, in the literature and yet for early feasibility work, they were spectacular.

00:12:32.750 --> 00:12:38.659
And I know then and they're very, very highly regarded guys in the clinic.

00:12:38.809 --> 00:12:39.169
By the way.

00:12:39.171 --> 00:12:39.740
This is true.

00:12:39.740 --> 00:12:46.730
I think this true in every country and everywhere, there is a lot of talent out there that doesn't appear.

00:12:46.870 --> 00:12:48.019
I mean the journals,

00:12:48.139 --> 00:12:51.769
I agree with that statement in, I've seen it in Columbia as well.

00:12:51.950 --> 00:13:06.169
The thing is that the way hospitals or facilities working South America, it's kind of different from the way they work in the US most of facilities, at least in Colombia, they do not have full time stuff.

00:13:06.200 --> 00:13:23.139
I mean they don't have full time specialists, so especially our subcontractors and they work in three, four or five different facilities at the same time in they are not so much involved with the academic world or the research world per se.

00:13:23.289 --> 00:13:42.220
I mean there are operating, they are doing procedures and they are very skillful while they do and you cannot really judge how skillful a physician in Latin America is by the number of publications because you're not going to see a high number of public cases because you don't see many innovations coming out of Latin America for economic reasons.

00:13:42.221 --> 00:13:47.500
And we can name 20 other reasons, but it's a good point that you're bringing up about the publication a matter.

00:13:47.799 --> 00:13:54.340
I don't know what you would say, but I think a factor is, I'm going back to my first bracing experiences in Argentina.

00:13:54.759 --> 00:14:09.970
I think a big factor is as those fellows look at their hours of the day, if you look at how they're spending their hours, they is 24 hours in the day versus someone at a major u s research hospital.

00:14:10.090 --> 00:14:22.240
Those guys in the clinics in South America have a greater, a far greater burden of just patients that have to be seen.

00:14:22.299 --> 00:15:00.830
And I think that that comes at the expense of a shelf full of publications and research that's done for more either statistical or regulatory endpoints points rather than, it's one thing to be doing early feasibility work and breakthrough work and trying to get new therapies into the clinic for grossly underserved needs and it's quite another thing to be, it's a necessary thing, but to be doing large population based research where you're really trying to tease out the other end of the research, the population level stuff where I'm really trying to determine the broad based indications and guidelines and things like that.

00:15:01.009 --> 00:15:03.710
It's something that rich countries get to worry about.

00:15:04.159 --> 00:15:13.309
It's the nature of progress and you know, the country is rich enough and far enough along they get to worry about these small differences.

00:15:13.311 --> 00:15:26.779
If you look at the where tabby is now and we're deciding, you know, he'll look at the event rates and the inclusions that were things that are under study and were studying things, it would have an undreamed of 20 years ago in terms of progress.

00:15:27.690 --> 00:15:28.240
All right Jon.

00:15:28.269 --> 00:15:32.830
So let's talk about how to select a contract research organization in these countries.

00:15:32.831 --> 00:15:35.350
I mean, have you been involved with the selection process?

00:15:35.570 --> 00:15:39.490
Have you worked with the partner, a CRO in these countries?

00:15:40.059 --> 00:15:40.450
Oh yeah.

00:15:40.451 --> 00:16:00.460
Every country I've ever worked in, I think this transcends even Latin America, you are always well served to have the right local knowledge on your team and the difference between having the right local knowledge and having substandard local knowledge will become clear to you.

00:16:01.149 --> 00:16:03.490
You need guidance in these settings.

00:16:03.820 --> 00:16:11.139
Certainly the experience you and I have had together in Columbia, I just remembered in terms of a, I'll just speak to will, how you are able to help us.

00:16:11.500 --> 00:16:35.919
Just the logistics of getting devices into the country on every study is different and every device is different and lead times are different and I felt as though we did really well having your guys advising us on getting in and out of the country with the equipment because as you remember we had to, you know, everybody is doing a real study.

00:16:36.389 --> 00:16:41.509
There's the commercial devices that you're just purchasing and bringing into the country.

00:16:41.690 --> 00:16:42.309
Use in your study.

00:16:42.311 --> 00:16:44.379
Then there's your research devices.

00:16:44.679 --> 00:16:46.960
Then there's your research equipment.

00:16:47.320 --> 00:16:52.809
You know there's big suitcases full of stuff and you've got to get it into the country in a timely fashion.

00:16:53.309 --> 00:16:57.129
That requires expert advice because there's not one answer.

00:16:57.130 --> 00:17:02.169
There's an answer for the research devices and there's other answers for other things.

00:17:02.440 --> 00:17:04.000
Particularly when time is critical.

00:17:04.259 --> 00:17:13.990
You know, you're trying to schedule a research case now what you're going to be ready on a given day to do a case and it's not going to do to have most of what you need there.

00:17:13.990 --> 00:17:15.430
You need everything there.

00:17:16.420 --> 00:17:25.690
That's one of the really, for those who haven't done it, it may sound mundane, but it is really not mundane to get the armamentarium required onto the site.

00:17:26.559 --> 00:17:26.950
Totally.

00:17:27.309 --> 00:17:27.759
Yeah.

00:17:27.789 --> 00:17:44.079
One thing that he's particular about, at least in Colombia where my experience in clinical research is it's in fact Jon, that hospitals do not get involved with regulatory approval processes or submissions.

00:17:44.440 --> 00:17:53.039
They don't get involved with importation paperwork, anything related to the operational or administrative stuff of the study.

00:17:53.549 --> 00:17:57.930
They just concentrate on recruiting patients and performing the procedures.

00:17:58.410 --> 00:18:11.759
So it's kind of mandatory to seek local help for the administrative and regulatory importation activities that need to happen alongside the clinical activities.

00:18:12.170 --> 00:18:13.250
Yeah, absolutely.

00:18:13.279 --> 00:18:14.240
You're exactly right.

00:18:14.240 --> 00:18:16.220
I think again, that was a lot of these things.

00:18:16.221 --> 00:18:17.809
I was back just to my first experience.

00:18:17.810 --> 00:18:31.190
Certainly I look at starting in Argentina, you realize that within the four walls of the hospital, the major clinicians have a pretty wide ranging free hand.

00:18:31.670 --> 00:18:33.650
But that's all they do.

00:18:34.519 --> 00:18:44.420
Their zone is in the hospital and then as you described everything that's outside of the hospital and gets you to the doorway you need outside help on.

00:18:44.599 --> 00:19:03.440
And I think that's been pretty consistently my experience, the leading, the important principal investigators can usually gain ethics committee approval either from the site or from the regulatory people, but everything else is up to the company and their representatives.

00:19:03.910 --> 00:19:04.299
Yeah.

00:19:04.690 --> 00:19:05.079
Okay.

00:19:05.559 --> 00:19:11.829
So what about your experience with regulatory approvals in these countries at Jon?

00:19:12.250 --> 00:19:15.069
What's your perception of the submission process?

00:19:15.070 --> 00:19:17.349
I mean, was it fast for easy?

00:19:17.351 --> 00:19:19.329
Was it difficult, convoluted?

00:19:19.359 --> 00:19:20.740
Was there corruption involved?

00:19:20.920 --> 00:19:22.390
I mean, what's your take on all this?

00:19:22.930 --> 00:19:30.579
I would call Colombia reasonable and quirky, but you better have some local guidance.

00:19:31.299 --> 00:19:33.220
You know the words without.

00:19:33.339 --> 00:19:41.349
I think that your inputs to our team and then we had a good team a knew how to do regulatory submissions in a number of countries.

00:19:42.220 --> 00:19:54.759
I would say Columbia came in on the more reasonable end of the spectrum, but you know with some head scratchers, head scratchers, but not things where you just throw up your hands in despair.

00:19:54.760 --> 00:19:59.109
It was more, if you remember on the second and third go rounds.

00:19:59.111 --> 00:20:05.410
We had a few times where we had to go a few extra months working out small points.

00:20:05.890 --> 00:20:21.849
It was neither unduly burdensome nor unduly quirky and I don't think of the regulatory process as being a dominant driver for someone considering working in Columbia.

00:20:21.851 --> 00:20:28.450
I think to me you'd be considering the other factors I described earlier, well what are you testing?

00:20:29.500 --> 00:20:48.619
What kind of trial do you want to run and therefore do I gain specific advantages and I think the middle tier of difficulty and cardiovascular devices, things where you're going to want a highly skilled investigator but also be able to augment with some US help.

00:20:48.710 --> 00:20:52.339
That's a sweet spot for Columbia in the regulatory process.

00:20:52.430 --> 00:20:54.529
Not something to be terribly worried about.

00:20:55.140 --> 00:20:55.769
Very good.

00:20:56.220 --> 00:20:56.759
All right.

00:20:56.789 --> 00:20:59.670
What about the managing of the study, Jon?

00:20:59.880 --> 00:21:09.359
What's your experience or what's your perception about the way you interactions with this side with the staff or with your CRO in country?

00:21:10.000 --> 00:21:18.279
I think you must have a well connected local cro support of the center that is known to the center.

00:21:18.280 --> 00:21:51.759
I think your first decision criteria is going to be center and investigator driven and then whoever you're working with, you want them to be able to congenially support the center, but expect that the center is not going to have enough research staff on their own to take care of this study and you're for sure going to want a well-qualified cro to come in and help out the center in terms of completing the study execution.

00:21:51.789 --> 00:21:57.519
You know the kind of studies I've been involved and we do an echo follow up and cath follow up and things like that.

00:21:57.520 --> 00:21:59.019
Significant follow up.

00:21:59.440 --> 00:22:23.200
You want to provide the center with support the center as good peoples and the center wants to help from my experience, but if you were to attempt to try to do it based on the center only, you would almost certainly come to grieve, but the center will work well with, you know if you make the investment in providing the proper cro support, you'll do well.

00:22:23.579 --> 00:22:24.119
Excellent.

00:22:24.240 --> 00:22:24.539
All right.

00:22:24.540 --> 00:22:30.599
Jon, what about shipping and importation of investigational medical devices into a country, in Latin America.

00:22:31.079 --> 00:22:32.430
What's your experience with that?

00:22:32.990 --> 00:22:37.309
I would say if it wasn't for your guidance, we would have failed in Colombia.

00:22:38.740 --> 00:22:39.279
Thank you.

00:22:40.329 --> 00:22:58.690
My feeling with Columbia was if I just looked at the regs because it's a two sided thing, you have to be in line with us expectations and in line with Columbia and expectations and on the US side I think we were fine.

00:22:58.750 --> 00:23:16.900
We had our ducks in a row, but then on the Colombian side, your guidance was essential, but to me it was just a mixture of planned shipments and as we were calling them, emergency shipments, you know, short horizon shipments and you just want to get in sync with doing it.

00:23:17.109 --> 00:23:26.440
Things where you have the lead time, get them on site ahead of time and then do emergency in hand carry stuff on an as needed basis.

00:23:26.630 --> 00:23:27.140
Okay.

00:23:27.200 --> 00:23:27.769
Make sense.

00:23:28.299 --> 00:23:28.549
All right.

00:23:28.579 --> 00:23:33.740
What about the quality of the clinical data that you gather from Colombia or elsewhere in Latin America?

00:23:34.009 --> 00:23:36.170
What's your perception of the quality of that?

00:23:36.390 --> 00:23:54.440
I think the data's fine with the caveat I said earlier, you just want to make sure that you combined together by knowing who they are, you to know who your clinical coordinator at the site is and you want to know your cro personally and make sure that those two are hooked up together.

00:23:54.441 --> 00:24:01.160
They're put together and they understand what they have to execute, but then from there, no problem.

00:24:01.549 --> 00:24:20.119
Again for the kind of data on the cardiovascular data now I think mostly things like echo data and CT and x-ray and blood test and you know these are well understood things and and well executed and the timeliness and completeness is going to come down to your cro.

00:24:20.121 --> 00:24:22.400
Getting in touch with the hospital a day in advance.

00:24:22.569 --> 00:24:22.569
Yeah.

00:24:22.579 --> 00:24:24.259
Okay, I'm coming over tomorrow.

00:24:24.529 --> 00:24:26.420
We're following up on patient number.

00:24:26.769 --> 00:24:30.470
You know patients see four, seven one is going to get followed up on tomorrow.

00:24:30.471 --> 00:24:30.890
Right.

00:24:31.640 --> 00:24:35.660
Your range that the patient's going to be there and just the usual hard stuff.

00:24:35.661 --> 00:24:45.289
Getting the patient to the hospital and that means sometimes arranging for the transportation of the patient, whatever the case may be and you need people that are on the ball on the details.

00:24:45.480 --> 00:24:45.930
Okay.

00:24:46.079 --> 00:24:46.619
Very good.

00:24:47.410 --> 00:24:50.880
All right, Jon, what about hospital fees or cost savings?

00:24:50.970 --> 00:24:55.140
What's your overall perception of the savings seeing in a country like Colombia?

00:24:56.180 --> 00:24:57.980
I'll put my CEO hat on.

00:24:59.240 --> 00:25:03.349
Colombia is very much in, at least for cardiovascular studies.

00:25:03.630 --> 00:25:09.170
It's an ever changing test, but Colombia is in right in the middle in the competitive metal.

00:25:09.710 --> 00:25:16.009
As we know, there are a lot of factors in evaluating the costs of doing a study in a center in a country.

00:25:16.490 --> 00:25:24.200
And so I can't hair split on the matter, but costs was not a decisive factor, that's for sure.

00:25:24.890 --> 00:25:31.730
Not even a tertiary factor compared to the other alternatives that I've have experience with.

00:25:31.980 --> 00:25:32.369
Okay.

00:25:31.980 --> 00:25:33.059
Good, Jon.

00:25:34.059 --> 00:25:50.859
I have two items that they like to talk about; one is that something that you and I discussed before we started the episode privately is the fact that it's sponsor can own the lap.

00:25:51.569 --> 00:25:55.920
That's an expression that I use in our conversation in a country like Colombia.

00:25:56.130 --> 00:26:11.190
Can you elaborate on the advantages of having a team of physicians and engineers from the US coming to a lab in Colombia facility and a hospital in Colombia and pretty much operate and do whatever needs to be done to get their data that they need?

00:26:12.480 --> 00:26:13.019
Sure.

00:26:13.020 --> 00:26:21.089
And, and I should say that that's the experience I started with in Argentina to an even more profound sense than what I saw in Colombia.

00:26:21.720 --> 00:26:25.680
And I think it's the nearly ideal way to work.

00:26:26.190 --> 00:26:56.849
First of all, as we contemplate doing the case, you know of what our experience together was and that is, first I met with Pedro and then Pedro and our us clinicians did animal studies together and then I, with my clinical team visited Colombia and we just watched cases in your center and then we stepwise built up a synthetic team of clinicians from multiple centers support people from multiple centers.

00:26:56.880 --> 00:27:21.660
If you remember the whole exercise thing, we had obviously had special exercise study needs and we were able to set all those things up without dealing with superseding bureaucracy, getting in the way, the way there would be in any other settings either in terms of restricting the formation of the clinical team or restricting the support activities of the study.

00:27:21.980 --> 00:27:30.240
You know, I think it's an ideal setting and it goes to the sense of the clinic being clinician driven.

00:27:30.690 --> 00:27:32.880
The ownership is a fact, but I don't know.

00:27:33.019 --> 00:27:35.819
So what I associate with classic South American Clinic

00:27:37.339 --> 00:27:37.339
Okay.

00:27:38.930 --> 00:27:39.589
Very good.

00:27:40.279 --> 00:28:01.160
And the other topic I also wanting to talk about, John is the first thing human trial environment in the United States is my understanding that things have gotten a little issue in the u s to conduct first in human trials, but as steel companies are looking at countries like Colombia for their first in human trials.

00:28:01.519 --> 00:28:08.869
Why do you think is that the, why is it gotten better in the u s easier foster in the u s to conduct trials and why?

00:28:09.140 --> 00:28:12.049
Obviously with companies looking at other countries for those,

00:28:12.619 --> 00:28:15.769
yeah, we've kind of walked through it's old long history of it used to be pretty good.

00:28:15.839 --> 00:28:25.160
And if you go back to the 1960s, the US was the place for first in human work and then, you know, by the late nineties.

00:28:25.549 --> 00:28:26.210
Okay.

00:28:26.211 --> 00:28:28.400
Then in the two thousands, it was terrible.

00:28:28.401 --> 00:28:34.160
Just the FDA was really taking a very restrictive look at first in human studies.

00:28:34.161 --> 00:28:39.289
But then, you know, cooler heads prevailed since about 2012, 2013.

00:28:39.290 --> 00:28:45.049
We've had a very, um, constructive approach with the early feasibility studies and breakthrough studies.

00:28:45.050 --> 00:29:06.170
But still, I think the factors in the US are still considerable hurdle to start in the u s and if you can start six or 12 months sooner in South America, then you would start in the u s I think it's something to contemplate depending on the nature of the study, the nature of the method or device under investigation.

00:29:07.579 --> 00:29:19.190
I think the other thing we had talked about was the crossover realm of things that are across over device, between a structural interventional device and a surgical device.

00:29:19.940 --> 00:29:59.799
I think that's a particular place where South America can play a major role because I think that if you're going to do a study that's only going to last for an interim phase while you do a hybrid procedure, hybrid surgical interventional procedure, that could be just more challenging than it's worth to try to explain that into protocol in the u s um, and it might be just more straightforward to assemble your team in South America and work through that kind of work before you get a little more buttoned down and then do a US study.

00:30:00.119 --> 00:30:00.690
Okay.

00:30:01.150 --> 00:30:12.390
Jon, could you please quickly talk about patient recruitment in the US for first in human trials and getting the attention of facilities in the u s or study coordinators in the US as well?

00:30:12.920 --> 00:30:17.359
Yeah, I think depending on the field now, it can be a challenge.

00:30:18.529 --> 00:30:24.079
There are barriers that come with trying to explain studies and recruit patients.

00:30:24.279 --> 00:30:26.880
I'm hard pressed to simplify an answer though.

00:30:27.019 --> 00:30:30.619
Uh, the most important answer is it's situational specific.

00:30:30.740 --> 00:30:31.789
Depends on the device.

00:30:31.790 --> 00:30:33.019
It depends on the operator.

00:30:33.020 --> 00:30:46.789
It depends on the disease state, the patient's options, but overall recruitment is probably almost always going to be somewhat less challenging in South America.

00:30:46.910 --> 00:30:51.769
Then it's going to be in the United States as a probably be the most general thing I could say.

00:30:52.670 --> 00:30:54.109
Okay, that's fair enough.

00:30:54.559 --> 00:31:17.000
Yeah, and also the fact that in the u s senators are usually busier way B's here and there probably 20 startups running at the same time in a center in South America probably you find and basically get or that is doing procedures or like clinic where yours is the only study that he's running so you're going to have his own devoted attention to your project.

00:31:18.210 --> 00:31:19.019
Absolutely.

00:31:19.020 --> 00:31:20.369
That's a very good point.

00:31:20.371 --> 00:31:21.089
Big Research.

00:31:21.090 --> 00:31:37.200
Hospitals have a lot of research going on and yeah, I think the a lot of times is just, it's not as though the patients aren't there to be recruited, but rather the in hospital clinical staff have a tremendous burden on them.

00:31:37.380 --> 00:32:02.970
I think there's a lot more in house ownership of studies at the centers, an expectation that at the major centers, the in hospital people will own the study much more so than you might find in as we were talking earlier in South America, I think there's a more of an opportunity for a fluid assembly of both out of hospital and in hospital people.

00:32:03.750 --> 00:32:21.390
Whereas in the U s big center studies you have large teams of clinical people dedicated in the hospital, but large numbers of studies competing for their attention and they're not so flexible about dealing with outside staff and Crox.

00:32:21.730 --> 00:32:22.720
Very good.

00:32:23.200 --> 00:32:23.980
Excellent point.

00:32:24.599 --> 00:32:47.809
All right, John, um, before we close the show today, do you have knowledge or have you notified any major trends happening anywhere in the world, dad or relevant to Latin America in light of our discussion today, for example, you MDR, something like that.

00:32:48.380 --> 00:32:49.250
I didn't understand.

00:32:49.250 --> 00:32:50.569
What was the acronym you just said?

00:32:52.339 --> 00:32:54.019
EUMDR, the medical device regulation.

00:32:54.109 --> 00:32:54.769
Oh yeah, yeah.

00:32:54.829 --> 00:32:55.730
Oh absolutely.

00:32:55.910 --> 00:32:57.890
Before you said that, that's what I was going to say.

00:32:57.891 --> 00:33:04.970
I think that things are slowing down in Europe for complicated reasons and of course Europe is not Europe.

00:33:05.359 --> 00:33:08.329
There's still multiple paths there.

00:33:08.330 --> 00:33:19.670
But yeah, I think that the European situation is moving back closer to what it was two decades ago, which is slower and more challenging and more expensive.

00:33:20.509 --> 00:33:26.240
And that's an opportunity for South American centers to fill the void.

00:33:26.720 --> 00:33:26.960
Yeah.

00:33:26.961 --> 00:33:40.009
I think for whatever reason the Europeans are, I think as part of the whole European Union thing, they're just getting a little more particular about what they allow to happen and how the, how they allow it to happen is more barriers.

00:33:40.380 --> 00:33:40.619
Yeah.

00:33:40.621 --> 00:33:44.069
Everything really started because of the pip scandal out of France.

00:33:44.130 --> 00:33:52.589
The company that was making the breast implants and the European Commission decided to make their regulations a lot stricter.

00:33:53.099 --> 00:33:57.720
So clinical research is a major, major factor now in all devices.

00:33:58.049 --> 00:34:06.779
Even products that were not considered devices before the new medical device regulation on their, the directive now are considered, are officially devices.

00:34:06.780 --> 00:34:18.269
So you have all these 95 bodies BC with work and if you went to get a an inspection, you probably have to wait a year or so to get one.

00:34:18.719 --> 00:34:21.329
So it's really, really getting challenging in Europe.

00:34:21.360 --> 00:34:36.300
So it looks like Latin America would benefit from having European companies or u s companies to come and do their first in human trials because also the time before or US startup companies in their commercialization plans.

00:34:36.309 --> 00:34:37.650
What's your first, right?

00:34:37.750 --> 00:34:41.829
Yeah, Europe first beginning in the 1990s that wasn't true.

00:34:41.831 --> 00:34:46.989
But then as you moved into the two thousands boy, Europe really took the lead.

00:34:47.409 --> 00:34:57.880
Cause also some countries, as you probably remember are Argentina was really leading with a lot of first in human work and then things got more challenging there and things change.

00:34:57.909 --> 00:34:58.920
Yeah, things change.

00:34:59.489 --> 00:35:01.139
The only constant is change.

00:35:01.141 --> 00:35:02.880
I don't know who said it, but it's very accurate.

00:35:04.289 --> 00:35:04.500
Yeah.

00:35:04.501 --> 00:35:06.030
The only constant is change.

00:35:06.360 --> 00:35:06.510
Yeah.

00:35:06.510 --> 00:35:29.909
I have to say that would be a, if you could do one thing, if you're looking specifically at Columbia, it's a small enough country where if you could get the government people in the hospital, people to take a long view of we're going to establish supportive norms and stick with them so people will know what they're going to get.

00:35:30.000 --> 00:35:36.929
People that are considering doing a study this year, next year, the year after that, it won't be a surprise every year what they're dealing.

00:35:38.889 --> 00:35:39.989
That would be a real plus.

00:35:40.150 --> 00:35:42.639
That's what I'm trying to accomplish.

00:35:42.699 --> 00:35:44.619
That's my goal every single day.

00:35:45.190 --> 00:35:45.760
Believe me.

00:35:47.059 --> 00:36:03.260
I think that for the companies, that's the hardest thing where you're working and then you see these just wherever you are, the changes come along and always right after the changes come in, there's a period of time where everything slows down.

00:36:03.619 --> 00:36:18.889
While the companies and the notified bodies figure out what the changes mean and figure out how to deal with them and then things usually over time start getting better again, but wouldn't it be better if we could just have a stable way of doing things?

00:36:20.480 --> 00:36:21.500
Predictability.

00:36:22.139 --> 00:36:23.449
I think that's a word here.

00:36:25.010 --> 00:36:25.309
Yeah.

00:36:25.311 --> 00:36:27.530
Make things simple and predictable.

00:36:27.739 --> 00:36:28.130
Yeah.

00:36:28.369 --> 00:36:28.789
Yeah.

00:36:29.300 --> 00:36:36.380
I long for that day, you know, underneath that having been testing devices now for her word is 24 25 years.

00:36:36.739 --> 00:36:48.889
I think the underlying ethics and morals of studies haven't changed and the motivations, the motivations of ethical clinicians haven't changed.

00:36:48.920 --> 00:36:59.719
I realized that we have to be processes have to prevent against the unethical and the illegal, but most people aren't doing unethical and illegal things.

00:36:59.721 --> 00:37:16.820
They're trying to do the right thing and we want the processes to be fair and transparent and straightforward for people that are trying to do the right thing and develop things that are going to help patients and not just keep moving the goalposts gratuitously.

00:37:17.679 --> 00:37:18.130
Totally.

00:37:18.369 --> 00:37:18.699
Yeah.

00:37:19.500 --> 00:37:25.960
All right, Jon, before we close the show today are, do you have any final thoughts, store listeners?

00:37:26.230 --> 00:37:37.570
In other words, what will you say to the CEO of small startup company that is looking a destination to do their first human trial?

00:37:38.219 --> 00:37:42.780
I would say for sure talk to people who've been there.

00:37:42.840 --> 00:37:43.500
Done that.

00:37:43.679 --> 00:37:57.539
Either yourself or in other words, that the best thing is if as you're considering these things, if you've done it yourself before, but always be looking to talk to people who've been there and done that and be open minded about their new alternatives.

00:37:57.989 --> 00:38:06.300
And as you and I both know, I've had very favorable experiences in Columbia and a number of other countries and uh, be open minded about it.

00:38:07.630 --> 00:38:08.630
Very good, excellent.

00:38:08.630 --> 00:38:22.039
John, thank you so much as being a delightful conversation for me and I am sure listeners will find some good insights in your comments so I truly look forward to keeping in touch and thank you.

00:38:22.670 --> 00:38:23.630
Thank you, Julio.

00:38:23.789 --> 00:38:24.170
Good luck.

Jonathan Rourke, Co-Founder & CEO, MitraSpan

Listen On

Recent Episodes